Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report.

× No keyword cloud information.

11 in total

1. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors: Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal: Antimicrob Agents Chemother Date: 2012-06-04 Impact factor: 5.191

2. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors: E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal: Pharm Res Date: 2016-06-28 Impact factor: 4.200

3. Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.

Authors: Claire M Naftalin; Rupangi Verma; Meera Gurumurthy; Qingshu Lu; Matthew Zimmerman; Benjamin Chaik Meng Yeo; Kin Hup Tan; Wenwei Lin; Buduo Yu; Véronique Dartois; Nicholas I Paton
Journal: Antimicrob Agents Chemother Date: 2017-09-22 Impact factor: 5.191

4. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States.

Authors: M M Hannan; E P Desmond; G P Morlock; G H Mazurek; J T Crawford
Journal: J Clin Microbiol Date: 2001-02 Impact factor: 5.948

5. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.

Authors: Helen McIlleron; Roxana Rustomjee; Mahnaz Vahedi; Thuli Mthiyane; Paolo Denti; Catherine Connolly; Wasima Rida; Alexander Pym; Peter J Smith; Philip C Onyebujoh
Journal: Antimicrob Agents Chemother Date: 2012-03-12 Impact factor: 5.191

6. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors: Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal: Am J Respir Crit Care Med Date: 2013-07-01 Impact factor: 21.405

7. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.

Authors: Kwok-Chiu Chang; Chi-Chiu Leung; Wing-Wai Yew; Eric Chung-Ching Leung; Wai-Man Leung; Cheuk-Ming Tam; Ying Zhang
Journal: Antimicrob Agents Chemother Date: 2012-08-06 Impact factor: 5.191

8. JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors: Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal: J Infect Chemother Date: 2016-06-15 Impact factor: 2.211

Review 9. Challenges in the clinical assessment of novel tuberculosis drugs.

Authors: Kelly E Dooley; Patrick P J Phillips; Payam Nahid; Michael Hoelscher
Journal: Adv Drug Deliv Rev Date: 2016-01-28 Impact factor: 15.470

Review 10. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors: Dick Menzies; Andrea Benedetti; Anita Paydar; Ian Martin; Sarah Royce; Madhukar Pai; Andrew Vernon; Christian Lienhardt; William Burman
Journal: PLoS Med Date: 2009-09-15 Impact factor: 11.069